Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC)— Epidemiology Forecast to 2030

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC)— Epidemiology Forecast to 2030

  • May 2020 •
  • 100 pages •
  • Report ID: 5893091 •
  • Format: PDF
‘Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC)— Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted EGFR-NSCLC epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Understanding
Lung cancer mainly begins in the lungs, and it may spread to lymph nodes or other organs in the body, such as the brain. However, cancer from other organs may also spread to the lungs. When cancer cells spread from one organ to another, they are called metastases.
There are mainly two types of lung cancer small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC can be defined as any type of epithelial lung cancer other than SCLC. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas, and sarcomatoid carcinomas. Among these, Adenocarcinoma accounts for highest number of cases, i.e., approximately 47% followed by Squamous Cell Carcinoma and Large Cell Carcinoma.
There are several genetic mutations identified to play a major role in the progression of this indication. Mutations in EGFR, KRAS, and ALK are mutually exclusive in patients with NSCLC, and the presence of one mutation instead of another can influence response to targeted therapy.
Recent advances in understanding of cell signaling pathways that control cell survival have identified genetic and regulatory aberrations that suppress cell death, promote cell division, and induce tumorogenesis. One such discovery is that of EGFR. EGFR is a transmembrane receptor tyrosine kinase protein that is expressed in some normal epithelial, mesenchymal, and neurogenic tissue. Overexpression of EGFR has been reported and implicated in the pathogenesis of many human malignancies, including NSCLC. The EGFR gene may also undergo amplification, as detected by fluorescence in situ hybridization (FISH) or chromogenic in situ hybridization (CISH).
A large proportion of NSCLC patients have sensitizing mutations in exon 19 or 21 which activate the tyrosine kinase domain in EGFR. As per the secondary domain, it has been observed that mutations in EGFR are found more frequently in patients with adenocarcinomas, nonsmokers, patients of Asian ethnicity. It has been observed that EGFR mutation occurs in 35% cases of NSCLC in Japan, whereas in the United States it is around 20% of NSCLC cases.

Epidemiology Perspective
The EGFR-NSCLC epidemiology division provides the insights about historical and current patient pool and forecasted trend for each seven major countries. The EGFR-NSCLC epidemiology data are studied through EGFR-NSCLC possible division to give a better understanding of the Disease scenario in the 7MM.
The disease epidemiology covered in the report provides historical as well as forecasted Epidermal growth factor receptor-Non Small Cell Lung Cancer epidemiology [segmented as Total Incidence of NSCLC Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total EGFR-NSCLC cases, and Treated Patient Pool of EGFR-NSCLC] scenario of Epidermal growth factor receptor-Non Small Cell Lung Cancer in the 7MM covering the United States, EU5 countries (Germany, France, Italy , Spain, and the United Kingdom), and Japan from 2017 to 2030.

Epidermal growth factor receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Detailed Epidemiology Segmentation
• Total incident population of NSCLC in the 7MM was assessed to be 4,84,726 in 2017.
• The total incident cases of EGFR-NSCLC in the United States were found to be 37,370 in 2017 which is expected grow during the study period, i.e., 2017–2030.
• Estimates show the highest Incident population of EGFR-NSCLC is in the United States, which contributes to around 34% of the total population of EGFR mutated NSCLC in the 7MM (in 2017). Furthermore, among the European 5 countries, the Germany had highest incident population of NSCLC, estimated to be around 29%, which is further followed by the United Kingdom, France, Italy and Spain.
• In Asian population, the EGFR population is higher in comparison to other 7MM. Japan contributes to be around 32% to the total EGFR mutated NSCLC in the 7MM (in 2017).

Scope of the Report
• The EGFR-NSCLC report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
• The EGFR-NSCLC Report and Model provide an overview of the risk factors and global trends of EGFR-NSCLC in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan).
• The report provides insight about the historical and forecasted patient pool of EGFR-NSCLC in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of EGFR-NSCLC.
• The report provides the segmentation of the EGFR-NSCLC epidemiology by total Incidence of NSCLC in the 7MM.
• The report provides the segmentation of the EGFR-NSCLC epidemiology by total diagnosed cases of NSCLC patients by Stages in the 7MM.
• The report provides the segmentation of the EGFR-NSCLC epidemiology by Histology in the 7MM.
• The report provides the segmentation of the EGFR-NSCLC epidemiology by Treated Patient Pool of EGFR-NSCLC in the 7MM.

Report Highlights
• 11-Year Forecast of Epidermal growth factor receptor-Non Small Cell Lung Cancer epidemiology
• 7MM Coverage
• Total Incident Cases of Non-Small Cell Lung Cancer
• Incident Cases according to segmentation: Histology, EGFR-NSCLC
• Treated cases of EGFR-NSCLC

KOL-Views
We interview, KOL’s and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over EGFR-NSCLC scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Epidermal growth factor receptor-Non Small Cell Lung Cancer ?
• What are the key findings pertaining to the Epidermal growth factor receptor-Non Small Cell Lung Cancer epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017–2030)?
• What would be the total number of patients of Epidermal growth factor receptor-Non Small Cell Lung Cancer across the 7MM during the study period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2017–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of Epidermal growth factor receptor-Non Small Cell Lung Cancer?

Reasons to buy
The Epidermal growth factor receptor-Non Small Cell Lung Cancer Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Epidermal growth factor receptor-Non Small Cell Lung Cancer market
• Quantify patient populations in the global Epidermal growth factor receptor-Non Small Cell Lung Cancer market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Epidermal growth factor receptor-Non Small Cell Lung Cancer therapeutics in each of the markets covered
• Understand the magnitude of Epidermal growth factor receptor-Non Small Cell Lung Cancer population by its severity
• The Epidermal growth factor receptor-Non Small Cell Lung Cancer epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The Epidermal growth factor receptor-Non Small Cell Lung Cancer Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030
Total Incident cases of EGFR-NSCLC in the 7MM was assessed to be 1,11,060 in 2017, and are expected to increase during the study period. Among the European 5 countries, Germany had Incident population of EGFR-NSCLC. On the other hand, Spain had the lowest incident cases of EGFR-NSCLC in 2017.